Myelodysplastic Syndrome - Pipeline Review, H2 2017

Date: November 30, 2017
Pages: 962
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: MC7C49AFDC5EN
Leaflet:

Download PDF Leaflet

Myelodysplastic Syndrome - Pipeline Review, H2 2017
Myelodysplastic Syndrome - Pipeline Review, H2 2017

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Myelodysplastic Syndrome - Pipeline Review, H2 2017, provides an overview of the Myelodysplastic Syndrome (Oncology) pipeline landscape.

Myelodysplastic syndrome (MDS) is a condition that affects the bone marrow and the blood cells it produces. Myelodysplastic syndromes rarely cause signs or symptoms in the early stages of the disease. Symptoms include fatigue, shortness of breath, unusual paleness (pallor) due to anemia, easy or unusual bruising or bleeding and frequent infections.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Myelodysplastic Syndrome - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Myelodysplastic Syndrome (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Myelodysplastic Syndrome (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Myelodysplastic Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 14, 70, 56, 3, 21 and 5 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical, Discovery and Unknown stages comprises 9, 8, 3, 2 and 2 molecules, respectively.

Myelodysplastic Syndrome (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Myelodysplastic Syndrome (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Myelodysplastic Syndrome (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Myelodysplastic Syndrome (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Myelodysplastic Syndrome (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Myelodysplastic Syndrome (Oncology)
REASONS TO BUY
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Myelodysplastic Syndrome (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Myelodysplastic Syndrome (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


NOTE: Out of security concerns Global Markets Direct requires using corporate email address.
Introduction
Myelodysplastic Syndrome - Overview
Myelodysplastic Syndrome - Therapeutics Development
Myelodysplastic Syndrome - Therapeutics Assessment
Myelodysplastic Syndrome - Companies Involved in Therapeutics Development
Myelodysplastic Syndrome - Drug Profiles
Myelodysplastic Syndrome - Dormant Projects
Myelodysplastic Syndrome - Discontinued Products
Myelodysplastic Syndrome - Product Development Milestones
Appendix

LIST OF TABLES

Number of Products under Development for Myelodysplastic Syndrome, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.1), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.2), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.3), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.4), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.5), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.6), H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017 (Contd.1), H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd.1), H2 2017
Products under Development by Companies, H2 2017 (Contd.2), H2 2017
Products under Development by Companies, H2 2017 (Contd.3), H2 2017
Products under Development by Companies, H2 2017 (Contd.4), H2 2017
Products under Development by Companies, H2 2017 (Contd.5), H2 2017
Products under Development by Companies, H2 2017 (Contd.6), H2 2017
Products under Development by Companies, H2 2017 (Contd.7), H2 2017
Products under Development by Companies, H2 2017 (Contd.8), H2 2017
Products under Development by Companies, H2 2017 (Contd.9), H2 2017
Products under Development by Universities/Institutes, H2 2017
Products under Development by Universities/Institutes, H2 2017 (Contd.1), H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Target, H2 2017 (Contd.1), H2 2017
Number of Products by Stage and Target, H2 2017 (Contd.2), H2 2017
Number of Products by Stage and Target, H2 2017 (Contd.3), H2 2017
Number of Products by Stage and Target, H2 2017 (Contd.4), H2 2017
Number of Products by Stage and Target, H2 2017 (Contd.5), H2 2017
Number of Products by Stage and Target, H2 2017 (Contd.6), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd.1), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd.2), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd.3), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd.4), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd.5), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd.6), H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Myelodysplastic Syndrome - Pipeline by 4SC AG, H2 2017
Myelodysplastic Syndrome - Pipeline by AbbVie Inc, H2 2017
Myelodysplastic Syndrome - Pipeline by Acceleron Pharma Inc, H2 2017
Myelodysplastic Syndrome - Pipeline by Actinium Pharmaceuticals Inc, H2 2017
Myelodysplastic Syndrome - Pipeline by Aeglea BioTherapeutics Inc, H2 2017
Myelodysplastic Syndrome - Pipeline by Agios Pharmaceuticals Inc, H2 2017
Myelodysplastic Syndrome - Pipeline by Aileron Therapeutics Inc, H2 2017
Myelodysplastic Syndrome - Pipeline by AIMM Therapeutics BV, H2 2017
Myelodysplastic Syndrome - Pipeline by Altor BioScience Corp, H2 2017
Myelodysplastic Syndrome - Pipeline by Amgen Inc, H2 2017
Myelodysplastic Syndrome - Pipeline by Apogenix AG, H2 2017
Myelodysplastic Syndrome - Pipeline by Aprea AB, H2 2017
Myelodysplastic Syndrome - Pipeline by arGEN-X BV, H2 2017
Myelodysplastic Syndrome - Pipeline by Arno Therapeutics Inc, H2 2017
Myelodysplastic Syndrome - Pipeline by Array BioPharma Inc, H2 2017
Myelodysplastic Syndrome - Pipeline by Astex Pharmaceuticals Inc, H2 2017
Myelodysplastic Syndrome - Pipeline by AstraZeneca Plc, H2 2017
Myelodysplastic Syndrome - Pipeline by Atara Biotherapeutics Inc, H2 2017
Myelodysplastic Syndrome - Pipeline by Bayer AG, H2 2017
Myelodysplastic Syndrome - Pipeline by Bellicum Pharmaceuticals Inc, H2 2017
Myelodysplastic Syndrome - Pipeline by BerGenBio ASA, H2 2017
Myelodysplastic Syndrome - Pipeline by Bio-Path Holdings Inc, H2 2017
Myelodysplastic Syndrome - Pipeline by BioLineRx Ltd, H2 2017
Myelodysplastic Syndrome - Pipeline by BioLite Inc, H2 2017
Myelodysplastic Syndrome - Pipeline by Boehringer Ingelheim GmbH, H2 2017
Myelodysplastic Syndrome - Pipeline by Boston Biomedical Inc, H2 2017
Myelodysplastic Syndrome - Pipeline by Bristol-Myers Squibb Co, H2 2017
Myelodysplastic Syndrome - Pipeline by Calithera Biosciences Inc, H2 2017
Myelodysplastic Syndrome - Pipeline by Cantex Pharmaceuticals Inc, H2 2017
Myelodysplastic Syndrome - Pipeline by Celgene Corp, H2 2017
Myelodysplastic Syndrome - Pipeline by Cell Medica Ltd, H2 2017
Myelodysplastic Syndrome - Pipeline by Celldex Therapeutics Inc, H2 2017
Myelodysplastic Syndrome - Pipeline by Cellectis SA, H2 2017
Myelodysplastic Syndrome - Pipeline by Cellerant Therapeutics Inc, H2 2017
Myelodysplastic Syndrome - Pipeline by Celyad SA, H2 2017
Myelodysplastic Syndrome - Pipeline by CrystalGenomics Inc, H2 2017
Myelodysplastic Syndrome - Pipeline by CTI BioPharma Corp, H2 2017
Myelodysplastic Syndrome - Pipeline by Cyclacel Pharmaceuticals Inc, H2 2017
Myelodysplastic Syndrome - Pipeline by Daiichi Sankyo Co Ltd, H2 2017
Myelodysplastic Syndrome - Pipeline by Deciphera Pharmaceuticals LLC, H2 2017
Myelodysplastic Syndrome - Pipeline by Eisai Co Ltd, H2 2017
Myelodysplastic Syndrome - Pipeline by Eli Lilly and Co, H2 2017
Myelodysplastic Syndrome - Pipeline by Epizyme Inc, H2 2017
Myelodysplastic Syndrome - Pipeline by F. Hoffmann-La Roche Ltd, H2 2017
Myelodysplastic Syndrome - Pipeline by Fate Therapeutics Inc, H2 2017
Myelodysplastic Syndrome - Pipeline by FibroGen Inc, H2 2017
Myelodysplastic Syndrome - Pipeline by Forma Therapeutics Inc, H2 2017
Myelodysplastic Syndrome - Pipeline by Fortress Biotech Inc, H2 2017
Myelodysplastic Syndrome - Pipeline by Forty Seven Inc, H2 2017
Myelodysplastic Syndrome - Pipeline by Fujifilm Holdings Corporation, H2 2017
Myelodysplastic Syndrome - Pipeline by Gamida Cell Ltd, H2 2017
Myelodysplastic Syndrome - Pipeline by GlaxoSmithKline Plc, H2 2017
Myelodysplastic Syndrome - Pipeline by H3 Biomedicine Inc, H2 2017
Myelodysplastic Syndrome - Pipeline by Humanigen Inc, H2 2017
Myelodysplastic Syndrome - Pipeline by IGF Oncology LLC, H2 2017
Myelodysplastic Syndrome - Pipeline by Immune System Key Ltd, H2 2017
Myelodysplastic Syndrome - Pipeline by ImmunoGen Inc, H2 2017
Myelodysplastic Syndrome - Pipeline by Incyte Corp, H2 2017
Myelodysplastic Syndrome - Pipeline by Io Therapeutics Inc, H2 2017
Myelodysplastic Syndrome - Pipeline by Jazz Pharmaceuticals Plc, H2 2017
Myelodysplastic Syndrome - Pipeline by Jiangsu Hansoh Pharmaceutical Group Co Ltd, H2 2017
Myelodysplastic Syndrome - Pipeline by Johnson & Johnson, H2 2017
Myelodysplastic Syndrome - Pipeline by JW Pharmaceutical Corp, H2 2017
Myelodysplastic Syndrome - Pipeline by Kainos Medicine Inc, H2 2017
Myelodysplastic Syndrome - Pipeline by Karyopharm Therapeutics Inc, H2 2017
Myelodysplastic Syndrome - Pipeline by Kiadis Pharma NV, H2 2017
Myelodysplastic Syndrome - Pipeline by Kyowa Hakko Kirin Co Ltd, H2 2017
Myelodysplastic Syndrome - Pipeline by La Jolla Pharmaceutical Company, H2 2017
Myelodysplastic Syndrome - Pipeline by Les Laboratoires Servier SAS, H2 2017
Myelodysplastic Syndrome - Pipeline by Lixte Biotechnology Holdings Inc, H2 2017
Myelodysplastic Syndrome - Pipeline by MacroGenics Inc, H2 2017
Myelodysplastic Syndrome - Pipeline by Madrigal Pharmaceuticals Inc., H2 2017
Myelodysplastic Syndrome - Pipeline by Mateon Therapeutics Inc, H2 2017
Myelodysplastic Syndrome - Pipeline by medac GmbH, H2 2017
Myelodysplastic Syndrome - Pipeline by MediGene AG, H2 2017
Myelodysplastic Syndrome - Pipeline by MedImmune LLC, H2 2017
Myelodysplastic Syndrome - Pipeline by Medivir AB, H2 2017
Myelodysplastic Syndrome - Pipeline by MEI Pharma Inc, H2 2017
Myelodysplastic Syndrome - Pipeline by Merck & Co Inc, H2 2017
Myelodysplastic Syndrome - Pipeline by Merus NV, H2 2017
Myelodysplastic Syndrome - Pipeline by Millennium Pharmaceuticals Inc, H2 2017
Myelodysplastic Syndrome - Pipeline by Mirati Therapeutics Inc, H2 2017
Myelodysplastic Syndrome - Pipeline by Novartis AG, H2 2017
Myelodysplastic Syndrome - Pipeline by Onconova Therapeutics Inc, H2 2017
Myelodysplastic Syndrome - Pipeline by OncoTherapy Science Inc, H2 2017
Myelodysplastic Syndrome - Pipeline by Opsona Therapeutics Ltd, H2 2017
Myelodysplastic Syndrome - Pipeline by Pfizer Inc, H2 2017
Myelodysplastic Syndrome - Pipeline by Pharma Mar SA, H2 2017
Myelodysplastic Syndrome - Pipeline by Plexxikon Inc, H2 2017
Myelodysplastic Syndrome - Pipeline by Protagonist Therapeutics Inc, H2 2017
Myelodysplastic Syndrome - Pipeline by Rafael Pharmaceuticals Inc, H2 2017
Myelodysplastic Syndrome - Pipeline by Rich Pharmaceuticals Inc, H2 2017
Myelodysplastic Syndrome - Pipeline by Sorrento Therapeutics Inc, H2 2017
Myelodysplastic Syndrome - Pipeline by Stemline Therapeutics Inc, H2 2017
Myelodysplastic Syndrome - Pipeline by Sumitomo Dainippon Pharma Co Ltd, H2 2017
Myelodysplastic Syndrome - Pipeline by Sunesis Pharmaceuticals Inc, H2 2017
Myelodysplastic Syndrome - Pipeline by Syndax Pharmaceuticals Inc, H2 2017
Myelodysplastic Syndrome - Pipeline by Takara Bio Inc, H2 2017
Myelodysplastic Syndrome - Pipeline by Teva Pharmaceutical Industries Ltd, H2 2017
Myelodysplastic Syndrome - Pipeline by Tolero Pharmaceuticals Inc, H2 2017
Myelodysplastic Syndrome - Pipeline by Trillium Therapeutics Inc, H2 2017
Myelodysplastic Syndrome - Pipeline by VasGene Therapeutics Inc, H2 2017
Myelodysplastic Syndrome - Dormant Projects, H2 2017
Myelodysplastic Syndrome - Dormant Projects, H2 2017 (Contd.1), H2 2017
Myelodysplastic Syndrome - Dormant Projects, H2 2017 (Contd.2), H2 2017
Myelodysplastic Syndrome - Dormant Projects, H2 2017 (Contd.3), H2 2017
Myelodysplastic Syndrome - Dormant Projects, H2 2017 (Contd.4), H2 2017
Myelodysplastic Syndrome - Discontinued Products, H2 2017

LIST OF FIGURES

Number of Products under Development for Myelodysplastic Syndrome, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Number of Products by Top 10 Targets, H2 2017
Number of Products by Stage and Top 10 Targets, H2 2017
Number of Products by Top 10 Mechanism of Actions, H2 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Top 10 Molecule Types, H2 2017
Number of Products by Stage and Top 10 Molecule Types, H2 2017

COMPANIES MENTIONED

4SC AG
AbbVie Inc
Acceleron Pharma Inc
Actinium Pharmaceuticals Inc
Aeglea BioTherapeutics Inc
Agios Pharmaceuticals Inc
Aileron Therapeutics Inc
AIMM Therapeutics BV
Altor BioScience Corp
Amgen Inc
Apogenix AG
Aprea AB
arGEN-X BV
Arno Therapeutics Inc
Array BioPharma Inc
Astex Pharmaceuticals Inc
AstraZeneca Plc
Atara Biotherapeutics Inc
Bayer AG
Bellicum Pharmaceuticals Inc
BerGenBio ASA
Bio-Path Holdings Inc
BioLineRx Ltd
BioLite Inc
Boehringer Ingelheim GmbH
Boston Biomedical Inc
Bristol-Myers Squibb Co
Calithera Biosciences Inc
Cantex Pharmaceuticals Inc
Celgene Corp
Cell Medica Ltd
Celldex Therapeutics Inc
Cellectis SA
Cellerant Therapeutics Inc
Celyad SA
CrystalGenomics Inc
CTI BioPharma Corp
Cyclacel Pharmaceuticals Inc
Daiichi Sankyo Co Ltd
Deciphera Pharmaceuticals LLC
Eisai Co Ltd
Eli Lilly and Co
Epizyme Inc
F. Hoffmann-La Roche Ltd
Fate Therapeutics Inc
FibroGen Inc
Forma Therapeutics Inc
Fortress Biotech Inc
Forty Seven Inc
Fujifilm Holdings Corporation
Gamida Cell Ltd
GlaxoSmithKline Plc
H3 Biomedicine Inc
Humanigen Inc
IGF Oncology LLC
Immune System Key Ltd
ImmunoGen Inc
Incyte Corp
Io Therapeutics Inc
Jazz Pharmaceuticals Plc
Jiangsu Hansoh Pharmaceutical Group Co Ltd
Johnson & Johnson
JW Pharmaceutical Corp
Kainos Medicine Inc
Karyopharm Therapeutics Inc
Kiadis Pharma NV
Kyowa Hakko Kirin Co Ltd
La Jolla Pharmaceutical Company
Les Laboratoires Servier SAS
Lixte Biotechnology Holdings Inc
MacroGenics Inc
Madrigal Pharmaceuticals Inc.
Mateon Therapeutics Inc
medac GmbH
MediGene AG
MedImmune LLC
Medivir AB
MEI Pharma Inc
Merck & Co Inc
Merus NV
Millennium Pharmaceuticals Inc
Mirati Therapeutics Inc
Novartis AG
Onconova Therapeutics Inc
OncoTherapy Science Inc
Opsona Therapeutics Ltd
Pfizer Inc
Pharma Mar SA
Plexxikon Inc
Protagonist Therapeutics Inc
Rafael Pharmaceuticals Inc
Rich Pharmaceuticals Inc
Sorrento Therapeutics Inc
Stemline Therapeutics Inc
Sumitomo Dainippon Pharma Co Ltd
Sunesis Pharmaceuticals Inc
Syndax Pharmaceuticals Inc
Takara Bio Inc
Teva Pharmaceutical Industries Ltd
Tolero Pharmaceuticals Inc
Trillium Therapeutics Inc
VasGene Therapeutics Inc
Skip to top


Premenstrual Syndrome - Pipeline Review, H2 2017 US$ 2,000.00 Oct, 2017 · 28 pages
Fragile X Syndrome - Pipeline Review, H1 2016 US$ 2,000.00 Apr, 2016 · 95 pages
Premenstrual Syndrome - Pipeline Review, H1 2017 US$ 2,000.00 Mar, 2017 · 28 pages
Polycystic Ovarian Syndrome - Pipeline Review, H1 2018 US$ 2,000.00 Feb, 2018 · 45 pages

Ask Your Question

Myelodysplastic Syndrome - Pipeline Review, H2 2017
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: